BAY 80-6946
Showing 1 - 25 of 6,405
Locally Advanced Malignant Solid Tumor, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Solid Tumor Trial
Withdrawn
- Locally Advanced Malignant Solid Neoplasm
- +3 more
- (no location specified)
May 24, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte, New Haven (Copanlisib Hydrochloride,
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Copanlisib Hydrochloride
- Venetoclax
-
Duarte, California
- +1 more
Aug 3, 2022
Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Trial in Tampa (Cisplatin, Gemcitabine, Copanlisib)
Completed
- Biliary Carcinoma
- +3 more
- Cisplatin
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Aug 3, 2021
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,
Recruiting
- Deleterious BRCA1 Gene Mutation
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Aug 23, 2022
Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of
Active, not recruiting
- Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
- Copanlisib (BAY80-6946)
-
Multiple Locations, TaiwanMany Locations
Jan 31, 2023
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal
Recruiting
- Platinum-Refractory Fallopian Tube Carcinoma
- +11 more
- Copanlisib Hydrochloride
- +4 more
-
Aurora, Colorado
- +2 more
Dec 8, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid System Tumor Trial in Philadelphia (Biopsy,
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Biopsy
- +3 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Aug 5, 2022
Mature T-Cell and NK-Cell Tumor Trial in Hwasun-gun (Copanlisib, Gemcitabine)
Completed
- Mature T-Cell and NK-Cell Neoplasm
-
Hwasun-gun, Jeollanam-do, Korea, Republic ofChonnam National University Hwasun Hospital
Jun 9, 2022
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)
Terminated
- Estrogen Receptor Positive
- +16 more
- Biopsy of Breast
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022
Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)
Recruiting
- Chronic Lymphocytic Leukemia
- +6 more
- Copanlisib
- Nivolumab
-
Duarte, California
- +2 more
Mar 9, 2022
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Canada, United
Recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- Biopsy
- +6 more
-
Boston, Massachusetts
- +5 more
Jan 7, 2023
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in United States
Recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- Biopsy
- +7 more
-
Aurora, Colorado
- +7 more
Nov 29, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +4 more
- Abemaciclib
- +2 more
-
Birmingham, Alabama
- +12 more
Nov 9, 2022
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Suspended
- Anatomic Stage III Breast Cancer AJCC v8
- +12 more
- Copanlisib Hydrochloride
- Eribulin Mesylate
-
Gainesville, Florida
- +10 more
Nov 16, 2022
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Copanlisib
- +2 more
-
Los Angeles, California
- +4 more
Jul 19, 2022
Medical Oncology Trial in Canada, United States (Copanlisib (BAY80-6946), Itraconazole, Rifampin)
Completed
- Medical Oncology
- Copanlisib (BAY80-6946)
- +2 more
-
Dallas, Texas
- +4 more
Dec 11, 2020
Lymphoma Non-Hodgkin Trial in Japan (Copanlisib (BAY80-6946))
Completed
- Lymphoma Non-Hodgkin
- Copanlisib (BAY80-6946)
-
Nagoya, Aichi, Japan
- +12 more
Feb 21, 2022
Lymphoma, Non-Hodgkin Trial in Beijing (Copanlisib (Aliqopa, BAY80-6946))
Completed
- Lymphoma, Non-Hodgkin
- Copanlisib (Aliqopa, BAY80-6946)
-
Beijing, ChinaBeijing Cancer Hospital
May 17, 2021
Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (Aliqopa, BAY80-6946))
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Copanlisib (Aliqopa, BAY80-6946)
-
Birmingham, Alabama
- +100 more
Feb 10, 2022
Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma Trial in
Completed
- Endometrial Endometrioid Adenocarcinoma
- +5 more
- Copanlisib
- Laboratory Biomarker Analysis
-
New Haven, Connecticut
- +42 more
Jan 25, 2022
Hepatic Insufficiency, Renal Insufficiency Trial in Kiel, Bucuresti (Copanlisib (ALIQOPA, BAY80-6946))
Completed
- Hepatic Insufficiency, Renal Insufficiency
- Copanlisib (ALIQOPA, BAY80-6946)
-
Kiel, Schleswig-Holstein, Germany
- +1 more
Apr 6, 2021
Advanced or Metastatic Solid Tumor Trial in Worldwide (Rogaratinib (BAY1163877), Copanlisib (BAY80-6946))
Completed
- Advanced or Metastatic Solid Tumor
- Rogaratinib (BAY1163877)
- Copanlisib (BAY80-6946)
-
Los Angeles, California
- +19 more
Jul 13, 2022
HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer Trial in Ireland, Spain (Copanlisib,
Terminated
- HER2-positive Breast Cancer
- +3 more
- Copanlisib
- Trastuzumab emtansine
-
Cork, Ireland
- +3 more
Dec 14, 2020
Carcinoma, Squamous Cell of Head and Neck Trial in France (Copanlisib, Cetuximab)
Terminated
- Carcinoma, Squamous Cell of Head and Neck
-
Angers, France
- +6 more
Mar 24, 2021